About half of the high – risk patients beginning statin therapy may necessitate additional treatment to lower their triglycerides and/or to raise their HDL-C. The R3i is responding to this important clinical problem critically. ‘Given the magnitude of the global epidemic of type 2 diabetes – especially in developing areas – targeting atherogenic dyslipidemia is crucial. As the only independent global research base focusing on this issue, the R3i is developing tips for evidence-based strategies to reduce residual vascular risk urgently. Currently, we are conducting the 1st world-wide epidemiological research, REALIST, to determine the prevalence of atherogenic dyslipidemia and consequent residual risk of cardiovascular events.Jacobs, Ph.D., Yannan Jiang, Ph.D., Nabin Paudel, B.Optom., Matthew Signal, Ph.D., Benjamin Thompson, D.Phil., Trecia A. Wouldes, Ph.D., Tzu-Ying Yu, Ph.D., and Jane E. Harding, D.Phil. For
AACR invites application for carcinoid and pancreatic neuroendocrine tumor study grant The American Association for Cancers Research is pleased to announce new grant-giving partnerships with the Caring for Carcinoid Foundation and the Raymond and Beverly Sackler Fund for the Arts and Sciences. The AACR is thrilled to partner with The Looking after Carcinoid Foundation and the Raymond and Beverly Sackler Fund for the Arts and Sciences, stated Margaret Foti, Ph.D., M.D.